Tumor Necrosis Factor Inhibitor Drugs Market size is assessed at USD 42.9 billion in 2024 and is set to cross USD 59.4 billion by the end of 2037, registering more than 2.5% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of tumor necrosis factor inhibitor drugs is evaluated at USD 43.9 billion.
The tumor necrosis factor inhibitor drugs market is expanding due to the rising incidence of autoimmune conditions such as psoriasis, inflammatory bowel disease, and rheumatoid arthritis and the growing need for efficient treatments has increased as knowledge and diagnosis of many illnesses. TNF inhibitors have evolved as an important aspect of treatment due to their effectiveness in treating the symptoms of various long-term inflammatory conditions.
The rising cost of healthcare and easier access to cutting-edge biological medicines in emerging markets are two other key growth drivers. Better autoimmune disease diagnosis and treatment choices are made possible by the increased investments made in healthcare infrastructure in these locations by both the public and commercial sectors. Furthermore, it is anticipated that continued research and development efforts to enhance the safety and efficacy characteristics of TNF inhibitors would result in the release of novel and inventive goods onto the market. Further driving tumor necrosis factor inhibitor drugs market expansion are TNF inhibitors' expanding applications and increasing clinical practice adoption owing to their shown long-term benefits.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
2.5% |
|
Base Year Market Size (2024) |
USD 42.9 billion |
|
Forecast Year Market Size (2037) |
USD 59.4 billion |
|
Regional Scope |
|
Drug Class (Adalimumab, Etanercept, Infliximab, Golimumab, Certolizumab Pegol)
Adalimumab segment is expected to account for tumor necrosis factor inhibitor drugs market share of more than 56.3% by the end of 2037 owing to its broad application in the treatment of autoimmune illnesses, safety record, and broad efficacy. Better clinical trial outcomes, a wide range of indications, and great patient and physician familiarity are all factors contributing to the segment's growth. tumor necrosis factor inhibitor drugs market share is also increased by the continuous development of novel formulations and delivery systems.
Furthermore, adalimumab is the first and only fully human monoclonal antibody approved by the U.S FDA for the treatment of rheumatoid arthritis, used to treat a variety of inflammatory conditions in adults and children, including those brought on by autoimmune diseases. In July 2023, Sandoz announced the launch of Hyrimoz, the only adalimumab HCF biosimilar approved in the U.S.
Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn’s disease, Psoriasis, Ulcerative colitis, Ankylosing spondylitis, Juvenile idiopathic arthritis, Hidradenitis Suppurativa)
In tumor necrosis factor inhibitor drugs market, rheumatoid arthritis segment is set to dominate revenue share of over 42.8% by 2037 owing to the rising prevalence of rheumatoid arthritis across the globe and rising product launches. As per a study by Research Nester, over 350 million individuals worldwide were estimated to have arthritis in 2021 and this number is projected to rise due to several factors, including the growing global burden of the aging population. Adalimumab, infliximab, and etanercept are examples of TNF inhibitors that are very successful in treating RA symptoms and delaying the course of the illness.
Due to their robust clinical performance and excellent safety records, biologic medications are now the mainstay of RA treatment. For example, in December 2019, Amgen announced that its AVSOLA for moderate-to-severe rheumatoid arthritis received U.S. FDA approval.
Our in-depth analysis of the tumor necrosis factor inhibitor drugs market includes the following segments
|
Drug Class |
|
|
Indication |
|
|
Route of Administration |
|
|
Distribution Channel |
|
North America Market Analysis
North America in tumor necrosis factor inhibitor drugs market is set to account for more than 38.6% revenue share by the end of 2037. This growth can be attributed to the presence of top pharmaceutical businesses and biopharmaceutical companies focused on developing cutting-edge TNF inhibitor drugs. Furthermore, the developed healthcare system and regulatory framework in North America make it easier for novel treatments to enter the market quickly and be adopted.
The region's dominant position in the global tumor necrosis factor inhibitor drugs market is further attributed to its high patient awareness and availability of cutting-edge therapy choices. For example, in February 2022, the United States Food and Drug Administration (FDA) accepted Pfizer Inc.'s request to examine the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA (adalimumab-AFB), a biosimilar of Humira (adalimumab).
The U.S. holds a significant position due to its highly developed healthcare system, high incidence of autoimmune illnesses, and a strong focus on research and development. The country’s well-established healthcare reimbursement system additionally makes these treatments more accessible, which increases their use. In May 2024, Teva Pharmaceuticals partnered with Alvotech to launch SIMLANDI, the first interchangeable high-concertation injection for the treatment of Crohn’s disease, adult plaque psoriasis, adult psoriatic arthritis, and adult rheumatoid arthritis.
Asia Pacific Market Analysis
Asia Pacific in tumor necrosis factor inhibitor drugs market is expected to experience a stable CAGR during the forecast period owing to the high prevalence of autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis, rising adoption of advanced solutions to manage these diseases, and improving healthcare infrastructure. India, South Korea, Japan, and China are some of the largest revenue-generating countries in the Asia Pacific.
Prominent producers, strong government initiatives, and an aging population are driving the China market for TNF inhibitor drugs. The overall market expansion in China is expected to be stimulated by increasing rheumatic disease occurrences, high awareness of the availability and efficacy of TNF inhibitors, increased investments made by various industrial companies in biosimilars, and increased support from regulatory boards for biosimilar approval.
In India, the market is expected to rise as a result of the rising elderly population, the high prevalence of autoimmune diseases, and increasing investments in developing cost-effective TNF inhibitor drugs.
The tumor necrosis factor inhibitor drugs market is characterized by a dynamic and fiercely competitive environment, with both well-established pharmaceutical giants and cutting-edge biotechnology companies driving the industry. The market is dominated by major firms such as AbbVie and Pfizer due to their brand recognition and a wealth of clinical data proving the medications' safety and efficacy. The competition is being heightened by more recent entrants, such as firms creating biosimilars and next-generation TNF inhibitors, providing more affordable options and maybe better therapeutic characteristics. Further altering the market is the continued focus of research and development on enhancing the selectivity and minimizing the adverse effects of TNF inhibitors.
Here are some leading players in the tumor necrosis factor inhibitor drugs market:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?